{"denoms":[{"counts":[{"groupId":"BG000","value":"375"},{"groupId":"BG001","value":"189"},{"groupId":"BG002","value":"564"}],"units":"Participants"}],"groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"BG000","title":"Rucaparib 600 mg Tablets"},{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"BG001","title":"Placebo Tablets"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"39","upperLimit":"84","value":"61"},{"groupId":"BG001","lowerLimit":"36","upperLimit":"85","value":"62"},{"groupId":"BG002","lowerLimit":"36","upperLimit":"85","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"375"},{"groupId":"BG001","value":"189"},{"groupId":"BG002","value":"564"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"21"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"292"},{"groupId":"BG001","value":"144"},{"groupId":"BG002","value":"436"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"75"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"190"}],"title":"RECIST CR"},{"measurements":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"374"}],"title":"RECIST / CA-125 PR"}]}],"description":"Complete and partial responses at baseline must have been reported according to RECIST v1.1, as assessed by CT/MRI, and GCIG CA-125 response criteria, and defined as: Complete Response (CR) i.e. absence of any detectable disease and CA-125\\<ULN; Partial Response (PR), ≥30% decrease in the sum of the longest diameter of measurable lesions or if non-measurable disease at baseline, a GCIG CA-125 response (least a 50% reduction in CA-125 levels from a pretreatment sample (which must have initially been 2xULN) and confirmed after ≥21 days). CA-125 must have been \\<ULN for all PRs.","paramType":"COUNT_OF_PARTICIPANTS","title":"Best Response from Previous Platinum Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"151"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"227"}],"title":"6-12 Months"},{"measurements":[{"groupId":"BG000","value":"224"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"337"}],"title":">12 Months"}]}],"description":"Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of measurable lesions, an unequivocal increase in existing non-measurable lesion(s), or the appearance of unequivocal new lesion(s).","paramType":"COUNT_OF_PARTICIPANTS","title":"Penultimate Progression-free (PF) Interval","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"100"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"304"},{"groupId":"BG001","value":"160"},{"groupId":"BG002","value":"464"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Bulky Lesions (lesion >20 mm) at Baseline","unitOfMeasure":"Participants"}]}